RIBOONCOSTAR
Live / Registered — Registered (as of 18 Mar 2025)
What this means for you
Registered since 18 Mar 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79386745
- Registration number
- 7726189
- Mark type
- Stylized text
- Filed
- 10 Nov 2023
- Published for opposition
- 28 Jan 2025
- Registered
- 18 Mar 2025
- Attorney of record
- Zhi Dong
Goods and services
- Class 005 — Pharmaceuticals: Medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceuticals for the treatment of cancer; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceuticals for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; dietetic food and beverages adapted for medical use; depuratives for the body; medicines for veterinary purposes, namely, veterinary preparations for the treatment and diagnosis of gastrointestinal diseases, cardiovascular diseases, metabolic diseases, and liver diseases; pesticides; dressings, medical; composite materials for dental purposes; diapers for pets
- Class 042 — Scientific and technological services: Technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development services; research in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design
Owner
Prosecution history
- 18 Oct 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 26 Sept 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 26 Sept 2025 — FINAL DISPOSITION PROCESSED
- 20 Jun 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 18 Jun 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 03 Jun 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 03 Jun 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 18 Mar 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 18 Mar 2025 — REGISTERED-PRINCIPAL REGISTER
- 28 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Jan 2025 — PUBLISHED FOR OPPOSITION
- 22 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Jan 2025 — EXAMINER'S AMENDMENT ENTERED
- 02 Jan 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED